Atlas, F-Prime provide launch money for Akrevia — a little biotech with big plans to design better drugs
A couple of veteran drug developers are guiding a stealthy startup dubbed Akrevia Therapeutics out into the open today after a pair of high-profile biotech investors blessed the operation with a $30 million launch round.
Akrevia is headed by scientist Tim Clackson, whose last role was running the R&D shop at Ariad until Takeda came in and bought it, and executive chairman Nessan Bermingham, whose last gig was CEO of the gene editing company Intellia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.